Compare Johnson & Johnson (JNJ) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vital Farms Inc — how do they compare? Johnson & Johnson trades at $249.4 (market cap $598.96B), while Vital Farms Inc trades at $13.31 (market cap $590.45M). The key difference: Johnson & Johnson is far larger — about 1014.4× Vital Farms Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| JNJ | VITL | |
|---|---|---|
Market Cap | $598.96B | $590.45M |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $52.41 |
52-Week Low | $164.36 | $8.28 |
Enterprise Value | $631.90B | $593.26M |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Vital Farms (VITL) trades at $13.76, up 1.55% with a bullish technical signal from moving averages. The company shows solid profitability with 6.1% net margin and 15.44% ROE, though recent earnings missed expectations in two of the last three quarters. Analyst consensus is positive with 56% buy ratings and a $13.50 price target, while news highlights declining short interest and ongoing class action lawsuits.
The stock presents a mixed outlook with strong fundamentals offset by legal risks and earnings volatility. Valuation appears reasonable with P/E of 13.02 and P/S of 0.79, but investors should weigh the class action litigation's potential impact against the company's operational strength in the natural foods sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
